Categories: News

Emerald Health Therapeutics Comments on Board Resignation

Vancouver, British Columbia–(Newsfile Corp. – August 11, 2021) –  Further to its press release of August 6th, Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) (“Emerald” or the “Company”) provides additional details regarding the resignation of Dr. Avtar Dhillon as director and executive chairman. On August 5th the Company became aware that Dr. Avtar Dhillon had been arrested in the United States and charged with violations of US federal securities laws with respect to trading in certain US companies unrelated to Emerald. On August 6th Dr. Dhillon resigned from all roles with the Company, as previously announced. On August 9th the Securities and Exchange Commission announced certain additional charges against Dr. Dhillon and certain other individuals not related to Emerald.

None of the allegations in the charges against Dr. Dhillon or any of the other individuals charged mention any improper trading of Emerald securities and the Company is not able to comment on the veracity of any of the allegations made against Dr. Dhillon or any of the other individuals charged. The Company is not aware of any improper trading in Emerald securities and no allegations have been made against any other person associated with Emerald, including any of its officers or other directors. The Company and its legal counsel are currently considering whether there are any additional steps they can take in the best interests of the Company and its shareholders.

About Emerald Health Therapeutics, Inc.

Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products, with an emphasis on science-based innovation and product excellence.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer

1(800) 757 3536 Ext. #5
Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92850

Staff

Recent Posts

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

1 hour ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

1 hour ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

1 hour ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

1 hour ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

2 hours ago